Literature DB >> 14724822

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

Jason M Hui1, Archana Sud, Geoffrey C Farrell, Priyanka Bandara, Karen Byth, James G Kench, Geoffrey W McCaughan, Jacob George.   

Abstract

BACKGROUND & AIMS: Chronic hepatitis C virus infection is associated with an increased prevalence of type 2 diabetes. We hypothesized that virus-induced insulin resistance may be a mechanism for fibrogenesis in chronic hepatitis C virus infection.
METHODS: In 260 hepatitis C virus-infected subjects, we examined the relationship between histological findings and anthropometric and biochemical data, including insulin resistance determined by the homeostasis model assessment (HOMA-IR). We also compared fasting serum insulin, C peptide, and HOMA-IR levels between the subset of 121 hepatitis C virus patients with stage 0 or 1 hepatic fibrosis and 137 healthy volunteers matched by sex, body mass index, and waist-hip ratio.
RESULTS: Hepatitis C virus-infected subjects with stage 0 or 1 hepatic fibrosis had higher levels of insulin, C peptide, and HOMA-IR (all P < or = 0.01) compared with matched healthy controls. In the 250 hepatitis C virus patients (fibrosis stage 0 to 4), viral genotype and portal, but not lobular, inflammation were univariate predictors of HOMA-IR. By multiple linear regression analysis, independent predictors of HOMA-IR included body mass index (P < 0.001), previous failed antiviral treatment (P < 0.001), portal inflammatory grade (P < 0.001), and genotype 3 status (P = 0.01). Genotype 3 had significantly lower HOMA-IR than other genotypes (which were comparable when adjusted for effects of the remaining independent predictors). HOMA-IR was an independent predictor for the degree of fibrosis (P < 0.001) and the rate of fibrosis progression (P = 0.03).
CONCLUSIONS: Hepatitis C virus may induce insulin resistance irrespective of the severity of liver disease, and this effect seems to be genotype specific. Further, our findings support the hypothesis that insulin resistance may contribute to fibrotic progression in chronic hepatitis C virus infection.

Entities:  

Mesh:

Year:  2003        PMID: 14724822     DOI: 10.1053/j.gastro.2003.08.032

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  180 in total

1.  Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection.

Authors:  Chao-Hung Hung; Jing-Houng Wang; Tsung-Hui Hu; Chien-Hung Chen; Kuo-Chin Chang; Yi-Hao Yen; Yuan-Hung Kuo; Ming-Chao Tsai; Sheng-Nan Lu; Chuan-Mo Lee
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

Review 2.  Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights.

Authors:  Gül Bahtiyar; John J Shin; Ayse Aytaman; James R Sowers; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2004-06       Impact factor: 4.810

Review 3.  Impact of liver diseases on the development of type 2 diabetes mellitus.

Authors:  Po-Shiuan Hsieh; Yen-Ju Hsieh
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

4.  Hepatitis C virus and insulin resistance/diabetes mellitus.

Authors:  Dawn M Torres; Stephen A Harrison
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

5.  Severe insulin resistance in a treatment-naive chronic hepatitis C patient.

Authors:  Omar Khokhar; Jacqueline Fischer
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

6.  Treatment uptake of patients with chronic hepatitis C: can we expect and do more?

Authors:  Chia-Yen Dai
Journal:  Dig Dis Sci       Date:  2010-12       Impact factor: 3.199

7.  The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C.

Authors:  Dina Hazem Ziada; Sherif El Saadany; Mohamed Enaba; Medhat Ghazy; Azza Hasan
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

8.  Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study.

Authors:  Yi-Min Mao; Min-De Zeng; Lun-Gen Lu; Mo-Bin Wan; Cheng-Zhong Li; Cheng-Wei Chen; Qing-Chuen Fu; Ji-Yao Wang; Wei-Min She; Xiong Cai; Jun Ye; Xia-Qiu Zhou; Hui Wang; Shan-Ming Wu; Mei-Fang Tang; Jin-Shui Zhu; Wei-Xiong Chen; Hui-Quan Zhang
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

9.  Effect of Peroxisome Proliferator-Activated Receptor-γ Coactivator-1 Alpha Variants on Spontaneous Clearance and Fibrosis Progression during Hepatitis C Virus Infection in Moroccan Patients.

Authors:  Raouia ElFihry; Mohcine Elmessaoudi-Idrissi; Fatima-Zahra Jadid; Imane Zaidane; Hajar Chihab; Mohamed Tahiri; Mostafa Kabine; Wafaa Badre; Isabelle Chemin; Agnes Marchio; Pascal Pineau; Sayeh Ezzikouri; Soumaya Benjelloun
Journal:  Virol Sin       Date:  2020-04-15       Impact factor: 4.327

10.  Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension.

Authors:  Tsuyoshi Ishikawa; Shogo Shiratsuki; Takashi Matsuda; Takuya Iwamoto; Taro Takami; Koichi Uchida; Shuji Terai; Takahiro Yamasaki; Isao Sakaida
Journal:  J Gastroenterol       Date:  2013-10-05       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.